Inventiva S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IVA research report →
Range $14 – $14
Price Chart
About the company
Inventiva S. A. is a biopharmaceutical firm currently in the clinical development phase, specializing in creating orally administered small molecule treatments for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other ailments.
- CEO
- Andrew Obenshain
- IPO
- 2020
- Employees
- 77
- HQ
- Daix, BF, FR
Get TickerSpark's AI analysis on IVA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $163.22M
- P/E
- -5.97
- Fwd P/E
- 85.64
- PEG
- -0.04
- P/S
- 15444.08
- P/B
- 14.68
- EV/EBITDA
- -17.60
- Div Yield
- 0.00%
- Gross Margin
- -5232.65%
- Op Margin
- -306726.53%
- Net Margin
- -505557.14%
- ROE
- -1625.48%
- ROIC
- -74.76%
Latest fiscal year · YoY change
- Revenue
- $4.48M-51.3%
- Gross Profit
- $1.51M-83.6%
- Op Income
- $-130,946,540
- Net Income
- $-340,161,126-84.7%
- EPS
- $-1.82+48.6%
- OCF Growth
- -17.5%
- FCF Growth
- -17.3%
- 52W High
- $7.29
- 52W Low
- $2.82
- 50D MA
- $3.54
- 200D MA
- $4.69
- Beta
- 0.91
- RSI (14)
- 45
- Avg Volume
- 2.36M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Inventiva said it remains on track for Q4 2026 top-line NATiV3 data in MASH, with a strengthened balance sheet and cash runway into mid-2027.· September 28, 2026
- NATiV3 remains on schedule for top-line results in Q4 2026; last patient completed the final 72-week visit earlier this month.
- Management highlighted lanifibranor’s differentiated pan-PPAR profile and reiterated confidence based on the positive NATIVE phase II-B data.
- The company said the main NATiV3 cohort enrolled 1,009 patients with biopsy-confirmed non-cirrhotic MASH and F2/F3 fibrosis; the broader trial enrolled about 1,400 patients including an exploratory cohort.
- Inventiva said its June capital-structure actions materially improved liquidity and simplified the balance sheet, supporting runway to the end of Q2 2027.
- Management emphasized commercial and regulatory preparation, including plans for a potential NDA filing in H1 2027 and a possible U.S. launch in 2028 if data are positive.
As of June 30, 2026, Inventiva had EUR 233.9 million of combined cash equivalents and short-term deposits. In the first half of 2026, R&D expenses were EUR 46.2 million, marketing and business development expenses were EUR 2.6 million, and G&A expenses were EUR 22.2 million. The company said it bought back approximately 60% of the EIB warrants with anti-dilution protection for EUR 50 million, repaid EUR 63 million of EIB loans, secured new debt financing of up to EUR 130 million, and completed an ADS offering generating gross proceeds of EUR 103 million. Management said current resources and completed financing provide cash runway until the end of Q2 2027; if Tranche 3 warrants and Tranche C are fully completed, runway could extend to the start of Q1 2028. No revenue or EPS figures were provided on the call. Forward-looking milestones: NATiV3 top-line data in Q4 2026, potential FDA NDA submission in H1 2027, and a potential U.S. commercial launch in 2028.
Andrew Obenshain framed the quarter as a defining period, with the company focused on three priorities: finalizing NATiV3, preparing for regulatory filing, and building commercial readiness. He repeatedly stressed that lanifibranor is designed to address both the metabolic and hepatic drivers of MASH and said the program could fit multiple patient segments if approved. His tone was confident and constructive, with emphasis on differentiation, unmet need, and being prepared to move quickly after the data readout.
Axel-Sven Malkomes said the June financing transactions strengthened the balance sheet, extended debt maturity, and simplified the capital structure. He cited EUR 233.9 million of cash equivalents and short-term deposits at June 30, 2026, R&D expense of EUR 46.2 million, marketing and business development expense of EUR 2.6 million, and G&A expense of EUR 22.2 million. He said the company has runway through Q2 2027, and potentially to Q1 2028 if Tranche 3 warrants and Tranche C are completed after positive data. He did not provide revenue guidance, and said the company does not guide on future raises.
Most analyst questions focused on how investors should think about the two NATiV3 doses, weight gain and edema, F2/F3 mix, GLP-1 and SGLT2 drop-ins, and whether the company has enough visibility on blinded trial data to interpret the readout. Management said that if both doses are statistically significant, both could potentially be taken forward, but the decision will depend on efficacy and tolerability data. On safety, they said weight gain and edema are mechanistically expected with partial PPAR-gamma activity, generally mild to moderate, and not viewed as the main reason for discontinuation in the phase II experience. On GLP-1/SGLT2 background therapy, they said sensitivity analyses are pre-specified but the trial is not powered on those subgroups, and they do not expect the allowed non-MASH-dose GLP-1 drop-ins to materially affect histology.
The bullish case from this call is that Inventiva believes lanifibranor remains differentiated, with a mechanism meant to address both metabolic and fibrotic drivers of MASH and prior phase II-B signals across histology. Management said NATiV3 is fully enrolled, the final visit is complete, and the company is financially funded into the key Q4 2026 readout and beyond. If the data are positive, the company is already preparing for NDA filing and commercial launch.
The key risks discussed are execution on the Q4 2026 phase III readout and whether the safety/tolerability profile, especially weight gain and edema, will limit uptake or differentiation. Management also acknowledged uncertainty about how two doses might compare commercially and said many questions about blinded phase III data cannot yet be answered. The company’s valuation case still depends heavily on a single upcoming data event, and management offered no quantitative top-line guidance before the readout.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 84.6%
- Shares Outstanding
- 51.98M
- Float Shares
- 43.97M
of shares held by institutions
88 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Caligan Partners LP | 9.19M | ▲ 1.02M |
| Samsara Biocapital, LLC | 6.31M | 0 |
| Citadel Advisors LLC | 6.24M | ▲ 4.46M |
| Fmr LLC | 4.75M | ▲ 4.07M |
| Franklin Templeton Inc | 4.59M | ▲ 1.95M |
| Millennium Management LLC | 3.33M | ▼ 184.76K |
| Aberdeen Group PLC | 3.15M | ▲ 837.94K |
| Nantahala Capital Management, LLC | 3.00M | ▲ 318.47K |
| Trails Edge Capital Partners, LP | 2.66M | 0 |
| Two Sigma Investments, LP | 2.63M | ▲ 1.90M |
| Squadron Capital Management LLC | 2.40M | ▼ 35.00K |
| Marshall Wace, Llp | 2.26M | ▲ 1.30M |
Held by 12 ETFs
Biggest fund positions in IVA by dollar value.
Our IVA coverage
Recent articles, reports, and earnings notes.
No research on IVA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IVA report →Inventiva: Significant Upside Potential Ahead Of Pivotal Liver Disease Readout
seekingalpha.com · Oct 14
Inventiva (NASDAQ:IVA) Sets New 12-Month Low – Here’s What Happened
defenseworld.net · Oct 13
3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead
marketbeat.com · Oct 10
Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference
gurufocus.com · Oct 9
Inventiva Eyes Q4 2026 Phase III MASH Data as Lanifibranor Nears Key Test
marketbeat.com · Oct 4
Inventiva (NASDAQ:IVA) Shares Gap Down – Here’s Why
defenseworld.net · Oct 3
Inventiva (NASDAQ:IVA) Shares Gap Up – Here’s What Happened
defenseworld.net · Oct 2
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Stock Has Consensus Price Target of $15.14
defenseworld.net · Oct 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.